Literature DB >> 18815253

Region-specific changes in the subcellular distribution of AMPA receptor GluR1 subunit in the rat ventral tegmental area after acute or chronic morphine administration.

Diane A Lane1, Andree A Lessard, June Chan, Eric E O Colago, Yan Zhou, Stefan D Schlussman, Mary Jeanne Kreek, Virginia M Pickel.   

Abstract

Opiate addiction is characterized by progressive increases in drug intake over time suggesting maladaptive changes in motivational and reward systems. These behaviors are mediated by dopaminergic neurons originating from the ventral tegmental area (VTA), and long-term changes of these dopaminergic neurons are attributed to increased postsynaptic glutamatergic activation. Indeed, chronic morphine administration is known to increase AMPA receptor glutamate receptor 1 (GluR1) subunit in the VTA. However, there is no ultrastructural evidence that morphine affects the expression or surface availability of GluR1 subunits in VTA neurons of defined distribution or transmitter phenotype. Therefore, we examined electron microscopic immunolabeling of GluR1 and tyrosine hydroxylase (TH) in two VTA regions of rats perfused 1 h after a single injection of morphine, or chronic morphine in intermittent-escalating doses for 14 d, and appropriate saline controls. Acute morphine administration produced a significant increase in GluR1 immunogold particles at the plasma membrane and postsynaptic densities in both TH- and non-TH-containing dendrites in the parabrachial VTA, a region that contains mainly prefrontal-cortical-projecting dopaminergic neurons involved in motivation and drug-seeking behavior. Chronic morphine administration maintained the increased synaptic GluR1 labeling in the parabrachial VTA, but also increased the number of GluR1-labeled synapses and TH immunoreactivity in dendrites of the paranigral VTA where substantially more dopaminergic neurons project to limbic structures implicated in locomotor activation and reward. These results demonstrate a region- and dose-dependent redistribution of GluR1-containing AMPA receptors, which is consistent with acute morphine activation of cortical-projecting VTA neurons and chronic morphine activation of limbic-projecting VTA neurons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18815253      PMCID: PMC2679682          DOI: 10.1523/JNEUROSCI.2151-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  53 in total

1.  Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons.

Authors:  Daniel Saal; Yan Dong; Antonello Bonci; Robert C Malenka
Journal:  Neuron       Date:  2003-02-20       Impact factor: 17.173

2.  Co-localization of AMPA receptor subunits in the nucleus of the solitary tract in the rat.

Authors:  Sue A Aicher; Sarita Sharma; Jennifer L Mitchell
Journal:  Brain Res       Date:  2002-12-27       Impact factor: 3.252

Review 3.  Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions.

Authors:  Susan R Sesack; David B Carr; Natalia Omelchenko; Aline Pinto
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

Review 4.  Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse?

Authors:  William A Carlezon; Eric J Nestler
Journal:  Trends Neurosci       Date:  2002-12       Impact factor: 13.837

5.  Modulation of the mesolimbic dopamine system by glutamate: role of NMDA receptors.

Authors:  B D Kretschmer
Journal:  J Neurochem       Date:  1999-08       Impact factor: 5.372

6.  Morphine withdrawal-induced abnormalities in the VTA: confocal laser scanning microscopy.

Authors:  Saturnino Spiga; Giuliana P Serra; M Cristina Puddu; Marzia Foddai; Marco Diana
Journal:  Eur J Neurosci       Date:  2003-02       Impact factor: 3.386

7.  NMDA glutamate but not dopamine antagonists blocks drug-induced reinstatement of morphine place preference.

Authors:  B Ribeiro Do Couto; M A Aguilar; C Manzanedo; M Rodríguez-Arias; J Miñarro
Journal:  Brain Res Bull       Date:  2005-01-30       Impact factor: 4.077

8.  Regulation of drug reward by cAMP response element-binding protein: evidence for two functionally distinct subregions of the ventral tegmental area.

Authors:  Valerie G Olson; Cyrus P Zabetian; Carlos A Bolanos; Scott Edwards; Michel Barrot; Amelia J Eisch; Thomas Hughes; David W Self; Rachael L Neve; Eric J Nestler
Journal:  J Neurosci       Date:  2005-06-08       Impact factor: 6.167

9.  Increased AMPA GluR1 receptor subunit labeling on the plasma membrane of dendrites in the basolateral amygdala of rats self-administering morphine.

Authors:  Michael J Glass; Paul J Kruzich; Eric E O Colago; Mary Jeanne Kreek; Virginia M Pickel
Journal:  Synapse       Date:  2005-10       Impact factor: 2.562

10.  Subject-regulated dosing alters morphine self-administration behavior and morphine-stimulated [35S]GTPgammaS binding.

Authors:  P J Kruzich; A C H Chen; E M Unterwald; M J Kreek
Journal:  Synapse       Date:  2003-03-15       Impact factor: 2.562

View more
  28 in total

1.  Afferent-specific AMPA receptor subunit composition and regulation of synaptic plasticity in midbrain dopamine neurons by abused drugs.

Authors:  Cameron H Good; Carl R Lupica
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

Review 2.  Multivesicular bodies in neurons: distribution, protein content, and trafficking functions.

Authors:  Christopher S Von Bartheld; Amy L Altick
Journal:  Prog Neurobiol       Date:  2011-01-07       Impact factor: 11.685

3.  Enhanced dendritic availability of μ-opioid receptors in inhibitory neurons of the extended amygdala in mice deficient in the corticotropin-releasing factor-1 receptor.

Authors:  Azra Jaferi; Ping Zhou; Virginia M Pickel
Journal:  Synapse       Date:  2011-01       Impact factor: 2.562

4.  Morphological and molecular changes in aging rat prelimbic prefrontal cortical synapses.

Authors:  Erik B Bloss; Rishi Puri; Frank Yuk; Michael Punsoni; Yuko Hara; William G Janssen; Bruce S McEwen; John H Morrison
Journal:  Neurobiol Aging       Date:  2012-06-22       Impact factor: 4.673

5.  Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease.

Authors:  Attila D Kovács; Angelika Saje; Andrew Wong; Gábor Szénási; Péter Kiricsi; Eva Szabó; Jonathan D Cooper; David A Pearce
Journal:  Neuropharmacology       Date:  2010-10-29       Impact factor: 5.250

6.  Spatial and intracellular relationships between the alpha7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mouse.

Authors:  A M Duffy; P Zhou; T A Milner; V M Pickel
Journal:  Neuroscience       Date:  2009-04-15       Impact factor: 3.590

7.  Involvement of AMPA/Kainate Glutamate Receptor in the Extinction and Reinstatement of Morphine-Induced Conditioned Place Preference: A Behavioral and Molecular Study.

Authors:  Ali Siahposht-Khachaki; Zahra Fatahi; Asal Yans; Fariba Khodagholi; Abbas Haghparast
Journal:  Cell Mol Neurobiol       Date:  2016-04-06       Impact factor: 5.046

8.  Chronic intermittent hypoxia reduces neurokinin-1 (NK(1)) receptor density in small dendrites of non-catecholaminergic neurons in mouse nucleus tractus solitarius.

Authors:  Andrée Lessard; Christal G Coleman; Virginia M Pickel
Journal:  Exp Neurol       Date:  2010-03-03       Impact factor: 5.330

9.  Bidirectional effects of fentanyl on dendritic spines and AMPA receptors depend upon the internalization of mu opioid receptors.

Authors:  Hang Lin; Paul Higgins; Horace H Loh; Ping-Yee Law; Dezhi Liao
Journal:  Neuropsychopharmacology       Date:  2009-03-18       Impact factor: 7.853

10.  The influences of reproductive status and acute stress on the levels of phosphorylated delta opioid receptor immunoreactivity in rat hippocampus.

Authors:  Suzanne R Burstein; Tanya J Williams; Diane A Lane; Margarete G Knudsen; Virginia M Pickel; Bruce S McEwen; Elizabeth M Waters; Teresa A Milner
Journal:  Brain Res       Date:  2013-04-11       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.